# Core Laboratories share price today (Core Laboratories Inc., CLB)

> Core Laboratories Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. CLB · Energy · Oil & Gas Equipment & Services · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/clb

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: $9.77 (−38.7% in a year)
- P/E: 28.9×, over 1 year
- Revenue (Jun 2026): $125 M (−4.3% on a year ago)
- Profit (Jun 2026): $5.8 M (−45.7% on a year ago)
- Operating margin: 7.4% (−2.4 points on a year ago)
- ROE: 11%, FY25
- ROIC: 5.2%, against a 8.7% cost of capital: −3.5 points

The main question: yearly earnings per share moved −4.5% while the share price moved −38.7%. ## What is the Core Laboratories share price today? Core Laboratories Inc.'s share price was $9.77 at the close on 3 November 2026. That is 29.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between $10 and $20, and at that close it was at the low of that range. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 31 weeks running. Over the last 1 year the share price moved −24% while the S&P 500 moved +21%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 2 April 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Core Laboratories pay? Core Laboratories Inc. paid $0.04 per share over the last four reported quarters. The most recent declaration was $0.01 for Jun 2026. At today's price of $9.77 that is a yield of 0.41%, based on dividends already paid, not a forecast. ## Which stock lists is Core Laboratories on? Core Laboratories is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Core Laboratories profitable? Core Laboratories Inc. earned $5.8 M of net profit in the Jun 2026 quarter, −45.7% on the same quarter a year earlier. Full-year FY25 profit was $30.4 M. Over 4 years profit has grown 10.7% a year on average. That is 4.7% of the quarter's revenue. The same quarter a year earlier earned $10.7 M. 1 of the last 12 reported quarters were loss-making. For the full year, FY25 profit was $30.4 M (−5.5% on the year before). Why profit moved: revenue changed −4.3% on a year earlier and the margin moved −2.4 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −311.8% and revenue +0.3%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Core Laboratories make, and is it growing? Core Laboratories Inc. reported $125 M of revenue in the Jun 2026 quarter, −4.3% on the same quarter a year earlier. Over 4 years it has grown 2.9% a year on average. The last full year, FY25, came in at $527 M. The last four reported quarters add to $519 M. FY25 revenue was $527 M, +0.5% on the year before. Recent pace: the last four quarters grew +0.3% on average, against 2.9% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +0.3%, against +0.5% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −18.2%, against +0.7% a year (rolling over). ## How much of every $100 of sales does Core Laboratories keep? Core Laboratories Inc.'s operating margin was 7.4% in the Jun 2026 quarter, 2.4 percentage points lower than the same quarter a year ago. Across 5 years it has been between 8.8% and 11.2%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −2.4 percentage points on the year while gross margin changed −1.7 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Core Laboratories' profit turning into cash? Over the last 3 years, 119% of Core Laboratories Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $37.0 M of operating cash against $30.4 M of profit. After $14.6 M of spending on assets, $22.4 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Core Laboratories' cash go? Core Laboratories Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $38.2 M on assets over the last 3 years. Averaged over those years that is 2.4% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $38.2 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Core Laboratories' P/E ratio, and how does it compare with its own history? Core Laboratories Inc.'s P/E is 28.9×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −4.5% while the price moved −38.7%. Earnings did better than the price, which pulled the multiple down within its own range. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Core Laboratories business getting better or worse? Core Laboratories Inc.'s business is getting worse. Profit and EPS growth are shrinking: profit growth is −18.2% in the latest quarter, against +162.0% at its best in 12 quarters, with ROCE steady at 8.6%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does Core Laboratories earn on its capital? Core Laboratories Inc. earned a ROE of 11% in FY25. Its return on capital used (ROIC) is 3.5 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 5.8% net margin and 0.90× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 5.8% net margin × 0.90× asset turnover × 2.15× leverage (assets divided by equity) ≈ 11.2% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 5.2% − 8.7% = −3.5 percentage points. The 8.7% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 5.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 8.3%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Core Laboratories have too much debt? Core Laboratories Inc. has total debt of $165 M against shareholder equity of $279 M as of Jun 2026, so its debt is 0.59× its equity. Year by year, that ratio went from 1.59 in FY21 to 0.60 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Core Laboratories shareholding pattern? 10.9% of Core Laboratories Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 7.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Core Laboratories from balance-sheet trouble? For Core Laboratories Inc., the Z-score is 3.08. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 3.08 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Core Laboratories rank in its industry? There is no score against its industry: Core Laboratories Inc. is not among the largest members shown in this industry comparison for Oil & Gas Equipment & Services. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Core Laboratories compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Core Laboratories in size? Core Laboratories is the 34th largest of 38 Oil & Gas Equipment & Services companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: ProFrac Holding Corp., HMH Holding Inc. and Oil States International, Inc. Just below it: Natural Gas Services Group, Inc., Ranger Energy Services, Inc. and North American Construction Group. ### Oil & Gas Equipment & Services companies close in size

1. [ProFrac Holding Corp.](https://www.sectoralpha.in/us/stocks/acdc) $759 million
2. [HMH Holding Inc.](https://www.sectoralpha.in/us/stocks/hmh) $733 million
3. [Oil States International, Inc.](https://www.sectoralpha.in/us/stocks/ois) $530 million
4. Core Laboratories Inc. $448 million
5. [Natural Gas Services Group, Inc.](https://www.sectoralpha.in/us/stocks/ngs) $408 million
6. [Ranger Energy Services, Inc.](https://www.sectoralpha.in/us/stocks/rngr) $328 million
7. [North American Construction Group Ltd.](https://www.sectoralpha.in/us/stocks/noa) $320 million

[All 38 Oil & Gas Equipment & Services companies, largest first](https://www.sectoralpha.in/us/sectors/oil-gas-equipment-services#all-companies)

### Companies close in size in other industries

1. [Nexxen International Ltd.](https://www.sectoralpha.in/us/stocks/nexn) $490 million · Advertising Agencies
2. [Aquestive Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/aqst) $488 million · Drug Manufacturers - Specialty & Generic
3. Core Laboratories Inc. $488 million
4. [Delcath Systems, Inc.](https://www.sectoralpha.in/us/stocks/dcth) $487 million · Medical Devices
5. [One Liberty Properties, Inc.](https://www.sectoralpha.in/us/stocks/olp) $487 million · REIT - Diversified

## What else do people ask about Core Laboratories? ### What were Core Laboratories's latest quarterly results? Core Laboratories Inc. reported revenue of $125 M and net profit of $5.8 M for the Jun 2026 quarter. Revenue fell 4.3% and profit fell 45.7% compared with a year earlier. Earnings per share were $0.13. The operating margin was 7.4%, 2.4 percentage points lower than a year earlier (as of 3 November 2026). ### What is Core Laboratories's market cap? Core Laboratories Inc.'s market capitalisation is $448 M at a stock price of $9.77. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Core Laboratories performing? Core Laboratories Inc.'s latest readings are below. In its latest quarter, revenue fell 4.3% and profit fell 45.7% compared with a year earlier. Over the past 13 weeks it has done worse than the S&P 500, for 31 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Core Laboratories's stock price go up? This page does not forecast Core Laboratories Inc.'s stock price. What it shows instead: the stock price is $9.77. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Does Core Laboratories have too much debt? Core Laboratories Inc. has a moderate amount of debt: its debt is 0.57× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### Where is Core Laboratories in its business cycle? Core Laboratories Inc.'s FY25 operating margin was 9.8%, against a 5-year range of 8.8% to 11.2%: the middle of its own range, neither a peak nor a low. The latest quarter was 7.4%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Core Laboratories story? The main question: yearly earnings per share moved −4.5% while the share price moved −38.7%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Core Laboratories a stock worth studying right now? What the numbers show: Core Laboratories Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.